Arg296
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg296  -  hnRNP K (human)

Site Information
PPPPPPGrGGrGGsr   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 476739

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 12 ) , mutation of modification site ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , cervical cancer ( 12 ) , cervical adenocarcinoma ( 12 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on hnRNP K:
phosphorylation ( 1 )
Effects of modification on biological processes:
cell motility, induced ( 1 )

References 

1

Tsai HY, et al. (2019) hnRNPK S379 phosphorylation participates in migration regulation of triple negative MDA-MB-231 cells. Sci Rep 9, 7611
31110205   Curated Info

2

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

3

Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837   Curated Info

4

Uhlmann T, et al. (2012) A method for large-scale identification of protein arginine methylation. Mol Cell Proteomics 11, 1489-99
22865923   Curated Info

5

Mulhern D (2012) CST Curation Set: 13536; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

6

Zhou J (2009) CST Curation Set: 6945; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

7

Zhou J (2009) CST Curation Set: 6944; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

8

Zhou J (2009) CST Curation Set: 6946; Year: 2009; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

9

K├Âlbel K, et al. (2009) Type I Arginine Methyltransferases PRMT1 and PRMT-3 Act Distributively. J Biol Chem 284, 8274-82
19158082   Curated Info

10

Possemato A (2009) CST Curation Set: 5998; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

11

Chiou YY, Lin WJ, Fu SL, Lin CH (2007) Direct mass-spectrometric identification of Arg296 and Arg299 as the methylation sites of hnRNP K protein for methyltransferase PRMT1. Protein J 26, 87-93
17191129   Curated Info

12

Ong SE, Mittler G, Mann M (2004) Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods 1, 119-26
15782174   Curated Info